- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Diagnosis, disease notification, and management of rapid eye movement (REM) sleep behavior disorder
-
- Shimohata Takayoshi
- Department of Neurology, Brain Research Institute, Niigata University
-
- Inoue Yuichi
- Department of Somnology, Tokyo Medical University, Yoyogi Sleep Disorder Center
-
- Hirata Koichi
- Department of Neurology, Dokkyo Medical University
Bibliographic Information
- Other Title
-
- Rapid eye movement（REM）睡眠行動障害の診断，告知，治療
Search this article
Description
<p>Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia characterized by dream enactment behavior during REM sleep. It has been demonstrated that patients with idiopathic RBD are at a significantly increased risk of developing one of the α-synucleinopathies later in life, and this is called “phenoconversion”. Although some physicians argue against disclosing information that could cause patients psychological stress, the patients also have a “right to know” about their own disease. Therefore, determining when and how to disclose this information, in addition to appropriate follow-up, is important. Clonazepam is the first choice of treatment for RBD associated with α-synucleinopathies. Since RBD is one of the premotor symptoms of α-synucleinopathies, and enables its early diagnosis, a combination of RBD and other examinations may contribute to the realization of a disease-modifying therapy. It is hoped that the early establishment of biomarkers could help predict the phenoconversion from RBD to α-synucleinopathies.</p>
Journal
-
- Rinsho Shinkeigaku
-
Rinsho Shinkeigaku 57 (2), 63-70, 2017
Societas Neurologica Japonica
